BPC-157 and TB-500 show up together in almost every soft-tissue research stack. The question most newcomers ask is fair: if they're studied for the same broad target, why run both? Why not pick one?
Because they do different things at the cellular level. TB-500 has one mechanism that BPC-157 does not. That single difference is why the pair gets stacked instead of swapped. This piece walks through what TB-500 actually does, why the twice-weekly dosing schedule matches the compound's biology, and how the BPC-157 stack splits the work between the two.
The one thing TB-500 does that BPC-157 cannot
TB-500 binds free G-actin. That sentence is the whole hook. G-actin is the loose, single- unit form of actin, the cytoskeletal protein that gives cells their shape and lets them move. Cells assemble G-actin into long chains called F-actin for movement and division. The ratio of free G-actin to assembled F-actin is one of the levers cells use to decide when to migrate and where.
By binding free G-actin and holding it in a sequestered pool, TB-500 shifts that balance. The published research describes this as the central biochemical activity of the compound. It changes the available substrate for cell migration patterns at soft-tissue research sites.
BPC-157 has no actin-binding activity. It acts on growth factor signaling and angiogenic pathways (the formation of new capillaries). Same broad research target. Different starting point. That's why stacking the two gives a wider mechanistic coverage than doubling the dose of either one.
What TB-500 is
TB-500 is a synthetic peptide built around the active region of thymosin beta-4, a 43-amino-acid protein found in nearly every human tissue. The synthetic fragment preserves the actin-binding sequence, which is the part of the protein responsible for the G-actin activity described above. The two are not chemically identical, but they share the mechanism that matters for the research use case.
The four documented effects
- Actin sequestration. The central biochemical activity. Binds free G-actin, shifts the polymerization balance, modulates cell migration patterns.
- Cell migration support. Endothelial and other progenitor cells appear to migrate to research sites more readily in experimental models.
- Anti-inflammatory signaling. Reported modulation of inflammatory markers in experimental soft-tissue models.
- Angiogenic support. Reported support of new capillary formation. This is the one pathway where TB-500 and BPC-157 overlap, and it's likely part of why the stack converges on shared downstream endpoints.
What does the TB-500 research signal cover?
The published experimental literature spans animal models of soft-tissue, cardiac, and ocular research, plus a smaller body of human observational data. Frequently cited research targets:
- Soft-tissue and ligament research models
- Tendon research models
- Cardiac muscle research models
- Corneal research models
- Skin research models
Phase 3 human registration trials are not in the published record. The compound is sold strictly as a research-use-only molecule.
Why twice-weekly dosing
TB-500 has a long plasma activity window. That biology supports the twice-weekly schedule (often Monday and Thursday). BPC-157, by contrast, has a shorter window and gets dosed daily. The split schedule is not arbitrary. It reflects the half-life difference between the two compounds.
Some research protocols compress the schedule to a once-weekly higher dose (4 to 5 mg). Others keep the split twice-weekly pattern. Both shapes show up in the published research community.
What is the standard TB-500 research cycle structure?
| Phase | Duration | Dose | Frequency |
|---|---|---|---|
| Loading | Weeks 1 to 4 | 2.0 to 2.5 mg | Twice weekly (Mon and Thu) |
| Loading (extended) | Weeks 1 to 6 | 2.0 to 2.5 mg | Twice weekly |
| Maintenance | Weeks 7 to 12 | 2.0 mg | Every 1 to 2 weeks |
| Wash-out | 4 to 8 weeks | off | Between back-to-back cycles |
How the BPC-157 stack splits the work
In the standard stacked cycle, the two compounds run on different schedules but for the same window:
- BPC-157: Daily subQ near the research site, 4 to 6 weeks at 250 to 500 mcg.
- TB-500: Twice weekly subQ anywhere, 4 to 6 weeks at 2.0 to 2.5 mg.
- Shared wash-out: Both compounds off for 4 to 8 weeks after the loading window before any repeat cycle.
BPC-157 handles the local growth factor and angiogenic signaling. TB-500 handles the actin sequestration and the migration of progenitor cells into the area. Two levers, two timelines, one window.
What are the TB-500 side effects from the literature?
- Injection site response. Mild redness or tenderness at the subQ site. Usually gone within hours.
- Mild fatigue. Occasional in the first week of loading. Self-limiting.
- Headache. Uncommon. Usually resolves with hydration.
- Mild flushing. A small minority of researchers report flushing in the hour after injection. Usually resolves within 30 minutes.
The reported side effect burden is low across the available research literature. As with BPC-157, the absence of large Phase 3 human registration trials limits what can be said about long-term safety with confidence.
How do you reconstitute and store TB-500?
Aion ships TB-500 in 5 mg and 10 mg vials. Standard mix for the 5 mg vial: 2 mL of bac water, giving 2.5 mg per mL or 25 mcg per insulin syringe unit. A 2.0 mg dose at that concentration is 0.8 mL or 80 units. A 2.5 mg dose is 1.0 mL or 100 units. Full walk-through in our reconstitution guide.
- Lyophilized, sealed: refrigerated at 2 to 8 C, stable for months
- Lyophilized, long-term: minus 20 C freezer for multi-year storage
- Reconstituted with bac water: refrigerated at 2 to 8 C, 4 to 6 week use window
What researchers track on a TB-500 cycle
- Pain or limitation score at the research site, daily (1 to 10)
- Range of motion at the research site, weekly
- Sleep quality, daily via wearable
- Function-specific test relevant to the site, weekly
- Resting heart rate, weekly average
What is the TB-500 bottom line?
TB-500 brings one mechanism to the soft-tissue research stack that BPC-157 does not: actin sequestration. That single biochemical lever is the reason the two get paired instead of swapped. The twice-weekly schedule fits the long plasma window. The 4 to 6 week loading cycle fits the published research framework. Log the loading window, log the recovery metrics, and let the maintenance taper handle the rest.
For the other half of the stack, see /research/bpc-157. For the broader soft-tissue connective tissue piece, see /research/ghk-cu.